REQUEST A DEMO
Total
USD $0.00
Search more companies

New Shin Pharm Ltd. (Gimpo) (South Korea)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: New Shin Pharm Ltd. Profile Updated: December 09, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

New Shin Pharm Ltd. (Gimpo) is a company based in South Korea, with its head office in Gimpo. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers industry. The enterprise was incorporated on January 08, 2009. The total number of employees is currently 67 (2024). There was a net sales revenue increase of 10.72% reported in New Shin Pharm Ltd. (Gimpo)’s latest financial highlights for 2023. A growth of 17.87% was recorded in its total assets. In, 2023, the company’s net profit margin decreased by 0.04%.

Headquarters
46, Arayuk-ro 57(osipchil)beon-gil Gochon-eup Gimpo-si Gyeonggi
Gimpo; Gyeonggi; Postal Code: 415816

Contact Details: Purchase the New Shin Pharm Ltd. (Gimpo) report to view the information.

Basic Information
Total Employees:
Purchase the New Shin Pharm Ltd. (Gimpo) report to view the information.
Outstanding Shares:
Purchase the New Shin Pharm Ltd. (Gimpo) report to view the information.
Registered Capital:
Purchase the New Shin Pharm Ltd. (Gimpo) report to view the information.
Incorporation Date:
January 08, 2009
Key Executives
Purchase this report to view the information.
Chairman
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
C&N Medical Inc
71.5%
Company Performance
Financial values in the chart are available after New Shin Pharm Ltd. (Gimpo) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
10.72%
Total operating revenue
10.72%
Operating profit (EBIT)
-11.42%
EBITDA
-11.56%
Net Profit (Loss) for the Period
7.54%
Total assets
17.87%
Total equity
8.46%
Operating Profit Margin (ROS)
-0.32%
Net Profit Margin
-0.04%
Return on Equity (ROE)
-0.11%
Debt to Equity Ratio
4.66%
Quick Ratio
0.03%
Cash Ratio
0.05%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?